#Switzerland #AliveDx #MosaiQ #Eysins #Autoimmune

AliveDx's Innovative Approach to Autoimmune Disease Diagnosis

In a groundbreaking development, AliveDx has recently announced the acquisition of the IVDR-CE mark for their MosaiQ AiPlex® CTDplus multiplex assay, marking a significant leap towards improving the diagnosis of systemic autoimmune rheumatic diseases (SARDs). This multiplex assay not only streamlines laboratory workflows but also accelerates the delivery of crucial patient information, thereby enhancing clinical decision-making.

Understanding Systemic Autoimmune Rheumatic Diseases

Systemic autoimmune rheumatic diseases encompass various conditions, including Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus, and Systemic Sclerosis. These diseases affect millions globally and are characterized by the production of autoantibodies, complicating their diagnosis due to overlapping symptoms and variations among patients. The challenges faced in identifying these diseases often lead to lengthy delays in diagnosis and treatment.

Recognizing this pressing issue, AliveDx developed the MosaiQ AiPlex CTDplus multiplex assay. By employing a syndromic approach, the assay integrates multiple tests into a single platform. It examines a comprehensive autoantibody profile, thus facilitating quicker diagnosis through precise detection of various autoantibodies relevant to SARDs.

Features and Benefits of the MosaiQ AiPlex CTDplus Assay

With just a minimal sample volume of 10 μl from the patient, the MosaiQ AiPlex CTDplus allows for the testing of 15 key autoantibody markers known to be critical in diagnosing autoimmune diseases. By detecting antibodies like CCP, dsDNA, and Sm in one streamlined step, healthcare providers can obtain actionable insights quickly, supporting improved patient care.

The assay includes notable markers recommended by leading clinical guidelines (ACR/EULAR). Its ability to present a thorough profile significantly eases the decision-making process for clinicians, particularly in complex cases where symptoms overlap.

A Commitment to Better Patient Outcomes

Manuel O. Méndez, CEO of AliveDx, expressed excitement about achieving the fifth Clinical IVDR-CE mark in just 18 months, highlighting the company’s commitment to empowering healthcare professionals with advanced diagnostic tools. “Accurate and early diagnosis is essential for managing complex autoimmune diseases, and our MosaiQ AiPlex CTDplus assay supports laboratorians and clinicians in achieving this,” Méndez stated.

The MosaiQ platform is designed for efficiency, utilizing an automated microarray that can identify up to 1,275 disease markers per hour. This capability not only streamlines laboratory workflows but also maintains high accuracy and rapid turnaround times that align with modern healthcare expectations.

In addition to working on solutions for SARDs, AliveDx has plans to introduce multiplex testing for vasculitis and antiphospholipid syndrome, further solidifying their commitment to advancing diagnostic capabilities in the autoimmune disease landscape.

The Future of Autoimmune Diagnostics

Looking ahead, AliveDx aims to continue its mission of reshaping the future of diagnostic testing not only for autoimmune diseases but also for allergies and beyond. Their innovative approach has the potential to transform patient care by enhancing healthcare providers' ability to diagnose and manage conditions swiftly and effectively.

For more details about AliveDx’s diagnostic solutions and advancements in autoimmune disease diagnostics, interested parties can visit their official website at Alivedx.com.

Conclusion

AliveDx's MosaiQ AiPlex CTDplus multiplex assay is a significant advancement in the field of autoimmune diagnostics, providing timely and comprehensive testing solutions essential for improving patient outcomes. As the company continues to innovate, the healthcare community can anticipate an array of new diagnostic tools designed for enhanced efficiency and accuracy in patient care.